Background: Bladder cancer ranked ninth of principal male cancer in Malaysia. This study aimed to evaluate the clinical characteristics and survival of bladder cancer patients in Malaysia. Methods: A retrospective cohort study was conducted by obtaining records in the Malaysian National Cancer Registry. Patients aged 15 years old and above with diagnosis date between 2007 and 2011 were included. Death was updated until 31 December 2016. Five-year observed survival and median survival time were determined by the life table method and Kaplan–Meier estimate method. Results: Among 1828 cases, the mean (SD) age of diagnosis was 64.9 (12.5) years. The patients were predominantly men (78.7%), Malay ethnicity (49.4%) and transitional cell carcinoma (78.2%). Only 14.8% of patients were at stage I. The overall five-year observed survival and median survival time was 36.9% (95% CI: 34.6, 39.1) and 27.3 months (95% CI: 23.6, 31.0). The highest five-year observed survival recorded at stage I (67.6%, 95% CI: 62.0, 73.3) and markedly worsen at stage II (34.3%, 95% CI: 27.9, 40.8), III (25.7%, 95% CI: 18.7, 32.6) and IV (12.2%, 95% CI: 8.1, 16.3). Conclusions: Survival of bladder cancer patients in Malaysia was lower with advancing stage. The cancer control programme should be enhanced to improve survival.

中文翻译：

---

膀胱癌的生存和特征：马来西亚国家癌症登记处的分析

背景：膀胱癌在马来西亚的主要男性癌症中排名第九。这项研究旨在评估马来西亚膀胱癌患者的临床特征和生存率。方法：通过在马来西亚国家癌症登记处获得记录进行回顾性队列研究。年龄在15岁以上且诊断日期在2007年至2011年之间的患者。死亡更新至2016年12月31日。五年观察生存率和中位生存时间通过生命表方法和Kaplan-Meier估计方法确定。结果：在1828例病例中，平均诊断（SD）年龄为64.9（12.5）岁。患者主要是男性（78.7％），马来族（49.4％）和移行细胞癌（78.2％）。只有14.8％的患者处于I期。五年观察到的总生存时间和中位生存时间分别为36.9％（95％CI：34.6，39.1）和27.3个月（95％CI：23.6，31.0）。第一阶段记录的最高五年观察到存活率（67.6％，95％CI：62.0，73.3），第二阶段显着恶化（34.3％，95％CI：27.9，40.8），第三阶段（25.7％，95％CI ：18.7、32.6）和IV（12.2％，95％CI：8.1、16.3）。结论：马来西亚膀胱癌患者的生存率随着阶段的增加而降低。应加强癌症控制程序以提高生存率。随着阶段的发展，马来西亚膀胱癌患者的存活率较低。应加强癌症控制程序以提高生存率。随着阶段的发展，马来西亚膀胱癌患者的存活率较低。应加强癌症控制程序以提高生存率。